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F R O M T H E F A M I L Y P R A C T I C E I N Q U I R I E S N E T W O R K
Clinical  Inquiries
Does stimulant therapy 
help adult ADHD?
■ EVIDENCE-BASED ANSWER
Central nervous system stimulants improve symp-
toms of attention deficit–hyperactivity disorder
(ADHD) in adults (strength of recommendation:
B, based on an older, inconclusive systematic
review, a lesser-quality systematic review, and
several newer small randomized controlled trials).
Although not the focus of this question, 
nonstimulant medications (including buproprion,
modafinil, and guanfacine) have also been studied
in the treatment of ADHD in adults. Recently, 
atomoxetine became the only nonstimulant med-
ication to receive approval by the US Food and
Drug Administration for the treatment of ADHD.
■ EVIDENCE SUMMARY
A well-done systematic review of 12 trials
assessing the efficacy of stimulant therapy in the
treatment of adult ADHD did not find sufficient
evidence that stimulants were effective.1
Significant heterogeneity and poor reporting of
methodology was seen among the studies. 
The 1 study rated as high-quality was a 
7-week randomized controlled trial using a
crossover comparison of methylphenidate and
placebo.2  There was a favorable response in 78%
(18/23) of subjects while takin methylphenidate,
in contrast to 4% (1/23) while taking placebo
(number needed to treat [NNT]=1.4; P<.0001). A
favorable response was assessed by the Clinical
Global Impression Scale, a measure of illness
severity and improvement, and a >30% reduc-
tion in symptoms as measured by the ADHD
Rating Scale. A more recent, but less rigorous,
systematic review identified 15 studies of stimu-
lant efficacy in adults.3 Researchers concluded
that under controlled conditions, stimulants are
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efficacious in the treatment of ADHD in adults.
The rate of response among the studies ranged
from 25% to 78%. 
One of the better studies in this review was a
randomized, double-blind, 3-phase crossover
study of dextroamphetamine, modafinil (a drug
used to treat narcolepsy), and placebo.4 Each
phase was 2 weeks long, with a 4-day washout
in between. A favorable response was defined as
a reduction of ADHD symptoms by at least 30%
on the DSM-IV ADHD Behavior Checklist for
Adults. Dextroamphetamine and modafinil
showed the same response rate in 10 of 21
patients. Both treatments had a significant
improvement over placebo (P<.001). It was
unclear from the study what percentage of 
subjects responded to placebo. 
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A similar study compared dextroampheta-
mine, guanfacine (an antihypertensive agent),
and placebo in 17 patients.5 On the DSM-IV
ADHD Behavior Checklist for Adults, subjects
taking dextroamphetamine or guanfacine reported
similar decreases in mean ADHD scores com-
pared with placebo (24 vs 22 vs 30; P<.05). They
did not report the number of subjects who had a
30% reduction in symptoms. Of note: at the end
of the study but prior to unblinding, subjects were
asked which medication they preferred. Twelve
subjects chose dextroamphetamine, 4 chose
guanfacine, and 1 chose placebo. Subjects’ stated
reason for choosing dextroamphetamine was the
positive effect it had on their motivation. 
Another study included in this review was a
randomized controlled trial of mixed ampheta-
mine salts. Of the 27 adults who completed the
study, 19 (70%) responded favorably to mixed
amphetamine salts compared with 2 (7.4%)
receiving placebo (NNT=1.6; P<.001).6 Favorable
response was defined as more than a 30% reduc-
tion of symptoms on the ADHD Rating Scale. Not
included in either review was a 7-week random-
ized controlled trial comparing methylphenidate
with sustained-release buproprion.7 Thirty out of
37 subjects completed at least 1 week of the
study. The primary indicator of a favorable
response was the Clinical Global Impression
Scale. The rate of response was 50% for
methylphenidate, 64% for sustained-release
buproprion, and 27% for placebo (P<.14).
■ RECOMMENDATIONS FROM OTHERS
The American Academy of Child and Adolescent
Psychiatry8 concluded that stimulant medica-
tion can be used to treat adults who have been 
carefully evaluated. They recommend starting
methylphenidate, dextroamphetamine, or mixed 
amphetamine salts according to patient and 
clinician preference (Table). They do not recom-
mend the use of pemoline due to the potential
for hepatic failure.
Michelle E. Lutton, PsyD, Moses Cone Family Medicine
Residency Program, Greensboro, NC; Laura Leach, MLIS,
Carolinas Healthcare System, Charlotte, NC
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Appli
Stimulants used to treat ADHD in adults
Drug Starting dose Maximum daily dose
Methylphenidate 
Ritalin, Methylin 5 mg twice daily 65 mg*
Ritalin-SR, Methylin ER, 20 mg every morning      65 mg*
Metadate ER, Metadate CR
Concerta 18 mg every morning 54 mg 
Dextroamphetamine sulfate
Dexedrine 2.5 mg twice daily 45 mg*
Dexedrine spansules 5 mg every morning 45 mg*
Mixed amphetamine salts
Adderall 5 mg 40 mg
Adderall XR 10 mg every morning 30 mg
*American Academy of Child and Adolescent Psychiatry Practice Parameter
TA B L E  
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■ CLINICAL COMMENTARY
Medication can help even well-adapted
adults with ADHD
Stimulant therapy benefits many adult patients
with ADHD. While some adults need scheduled
dosing, others do well with as-needed dosing. 
Adults with ADHD often have made 
behavioral adaptations that allow success
without medication. Drugs help these patients
when focused attention is critical for specific
tasks. A salesman doing a month-end report
may find the improvement in attention helpful,
but not needed for most daily tasks. A college
student may need medication only for a specific
class or project. Physicians can help patients
with ADHD through anticipatory guidance in 
choosing a program of study or career goal and
then collaborating in choosing appropriate 
behavioral and medication therapies.
Daniel Triezenberg, MD, Family Practice Residency,
Saint Joseph Regional Medical Center, South Bend, Ind
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Does a high-fiber diet
prevent colon cancer 
in at-risk patients?
■ EVIDENCE-BASED ANSWER
There is no direct evidence of an effect of
dietary fiber on colon cancer incidence. A diet
high in fiber has not been shown to be effective
in the short-term (2- to 4-year) prevention of
recurrent colon polyps (strength of recommen-
dation [SOR]=A, based on consistent random-
ized clinical trials). Furthermore, epidemiologi-
cal evidence is inconsistent in demonstrating an
association between dietary fiber consumption
and the occurrence of colon cancer (SOR=C).
■ EVIDENCE SUMMARY
The term “dietary fiber” refers to a heteroge-
neous group of substances that may vary in
their biologic effects. Fiber is thought to reduce
the risk of colon cancer through the following
proposed mechanisms—decreased gastroin-
testinal transit time, increased stool bulk, and
fermentation of volatile fatty acids. Other
aspects of diet such as fat content, red meat,
and micronutrients may also play a role in the
development of colon cancer. 
Additional proposed risk factors include 
sedentary lifestyle, obesity, tobacco use, and 
alcohol consumption1; while the commonly
accepted high-risk groups for colon cancer are
those aged >60 years, those with a positive 
family history of colorectal cancer, and those
with familial polyposis syndrome. In summary,
it appears that the cause of colon cancer is com-
plex and multifactorial.
No randomized controlled trials of interven-
tions test whether increase dietary fiber affects
the development of colon cancer. Recent 
randomized controlled trials of interventions
have used colon polyps as a surrogate endpoint,
since it is believed that polyps are precursors to
cancer. A Cochrane meta-analysis2 of 5 trials
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